The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy

Hepatology

Volumn 61, Issue 5, 2015, Pages 1459-1461

  Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; PEGINTERFERON; TENOFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; GUANINE; MACROGOL DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; HEPATITIS B, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS;

EID: 84928206707     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27731     Document Type: Article

References (9)

1. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: a multicentre randomized trial (ARES study). Hepatology 2015;61(5):1512-1522.
2. Reijnders JG, Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? Hepatology 2013;58(6):1885-1887.
3. Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2014; doi: 10.1136/gutjnl-2014-307596.
4. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61(4):777-784.
5. Lampertico P, Brunetto MR, Craxì A, Gaeta GB, Rizzetto M, Palmieri G, et al. Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis [Abstract]. Hepatology 2014;60(1 Suppl.):LB-31.
6. Bourlière M, Rabiega P, Ganne-Carrié N, Serfaty L, Marcellin P, Pouget N, et al. HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg negative CHB patients on nucleos(t)ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings [Abstract 1863]. Hepatology 2014;60(Suppl.):1094A.
7. Yuen MF, Chan HLY, Given BD, Hamilton J, Schluep T, Lewis DL, et al. Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection [Abstract]. Hepatology 2014;60:(1 Suppl.):LB-21.
8. Su WW, Hsu CW, Lee CM, Peng CY, Chuang W-L, Kao J-H, et al. Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol 2014;60(1 Suppl.):S47.
9. Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial [Abstract 193]. Hepatology 2014;60(Suppl.):294A.